ClinicaliQ Trial Snapshot
- Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody — Recruiting • Phase II • Infectious Disease • NCT07285213.
- AZD5148 antibody reduces repeat Clostridioides difficile infections in adults compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above. Conditions: Clostridioides Difficile Infection Interventions: AZD5148, Placebo Lead Sponsor: AstraZeneca Planned Enrollment: 230 participants